Your browser doesn't support javascript.
loading
Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
Liang, Jiayu; Sun, Guangxi; Pan, Xiuyi; Zhang, Mengni; Shen, Pengfei; Zhu, Sha; Zhao, Jinge; Zheng, Linmao; Zhao, Junjie; Chen, Yuntian; Yin, Xiaoxue; Chen, Junru; Hu, Xu; Zeng, Yuhao; Chen, Jianhui; Wang, Yongquan; Liu, Zhihong; Yao, Jin; Su, Minggang; Huang, Rui; Liao, Banghua; Wei, Qiang; Li, Xiang; Zhou, Qiao; Liu, Jiyan; Shen, Yali; Liu, Zhenhua; Chen, Ni; Zeng, Hao; Zhang, Xingming.
Affiliation
  • Liang J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Sun G; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Pan X; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhang M; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Shen P; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhu S; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhao J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zheng L; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhao J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Chen Y; Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Yin X; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Chen J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Hu X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zeng Y; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Chen J; Department of Urology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Wang Y; Department of Urology, Southwest Hospital, Army Medical University, Chongqing, China.
  • Liu Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Yao J; Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Su M; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Huang R; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liao B; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Wei Q; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Li X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhou Q; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liu J; Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Shen Y; Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liu Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. zhliu@scu.edu.cn.
  • Chen N; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China. chenni1@163.com.
  • Zeng H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. kucaizeng@163.com.
  • Zhang X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. jarmin@scu.edu.cn.
Genome Med ; 15(1): 31, 2023 05 02.
Article in En | MEDLINE | ID: mdl-37131267
BACKGROUND: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare highly aggressive subtype of kidney cancer for which the distinct genomic, transcriptomic, and evolutionary relationships between metastatic and primary lesions are still unclear. METHODS: In this study, whole-exome, RNA-seq, and DNA methylation sequencing were performed on primary-metastatic paired specimens from 19 FH-RCC cases, including 23 primary and 35 matched metastatic lesions. Phylogenetic and clonal evolutionary analyses were used to investigate the evolutionary characteristics of FH-RCC. Transcriptomic analyses, immunohistochemistry, and multiple immunofluorescence experiments were performed to identify the tumor microenvironmental features of metastatic lesions. RESULTS: Paired primary and metastatic lesions generally showed similar characteristics of tumor mutation burden, tumor neoantigen burden, microsatellite instability score, CNV burden, and genome instability index. Notably, we identified an FH-mutated founding MRCA (the most recent common ancestor) clone that dominated the early evolutionary trajectories in FH-RCC. Although both primary and metastatic lesions manifested high immunogenicity, metastatic lesions exhibited higher enrichment of T effector cells and immune-related chemokines, together with upregulation of PD-L1, TIGIT, and BTLA. In addition, we found that concurrent NF2 mutation may be associated with bone metastasis and upregulation of cell cycle signature in metastatic lesions. Furthermore, although in FH-RCC metastatic lesions in general shared similar CpG island methylator phenotype with primary lesions, we found metastatic lesions displaying hypomethylated chemokine and immune checkpoints related genomic loci. CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Genome Med Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Genome Med Year: 2023 Document type: Article Affiliation country: Country of publication: